Important Information from the National Eye Institute Glaucoma is a major cause of vision loss in the U.S. While it currently affects about 3 million Americans, estimates show 6.3 million could have glaucoma by 2050. With Glaucoma Awareness Month in January, it’s a good time to think about scheduling a comprehensive dilated eye exam, especially [Read More]
Category: Latest News
Triple Therapy with Zeaxanthin Lessens Burden of Treatment for Wet AMD
As far back as 2007, triple therapy for wet (neovascular) age-related macular degeneration (AMD) was shown to be superior to mono therapy (intraocular injection of a single anti-VEGF drug).* And now, a study described in a recent online publication of the peer-reviewed monthly, International Journal of Retina and Vitreous, found that triple therapy supplemented with [Read More]
Delayed Dark Adaptation Predicts Onset of Dry AMD
A recent study* at the University of Alabama has found that measurement of the time it takes older adults’ eyes to adapt to the dark can predict onset of dry age-related macular degeneration (dAMD). Using a computerized dark adaptometer, 325 persons with healthy eyes were each subjected to a flash of light in one eye, [Read More]
X-82 Oral Medication May Reduce Number of Intravitreal Injections for Wet AMD
No cure yet exists for wet AMD, but three FDA-approved therapies are slowing the progress of wet AMD and reducing the amount of vision loss. These treatments are ranibizumab (Lucentis), aflibercept (Eylea), and off-label bevacizumab (Avastin). These medications are highly successful, but they must be injected directly into the eye, and the treatment often needs [Read More]
Iluvien Similar to Anti-VEGF Drugs as Treatment for Diabetic Retinopathy
(Updated 12/5/2017) On February 16, Charles C. Wykoff, MD, PhD, announced to the American Academy of Ophthalmology annual meeting that Iluviuan (fluocinolone acetonide) treatment, after 1.3 injections over 3 years in the FAME trials, “significantly reduced progression to prolific diabetic retinopathy from 31% to 17%, a similar reduction as observed with monthly anti-VEGF treatments.” Iluvian [Read More]